Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma

Author(s):  
Beatrice Dozin ◽  
Grazia Carbotti ◽  
Silvio Roncella ◽  
Paola Ferro ◽  
Paolo Dessanti ◽  
...  
Cytopathology ◽  
2021 ◽  
Author(s):  
Amber Louw ◽  
YC Gary Lee ◽  
Nathan Acott ◽  
Jenette Creaney ◽  
Chris Van Vliet ◽  
...  

2017 ◽  
Vol 12 (1) ◽  
pp. S1365-S1366
Author(s):  
Tobias Peikert ◽  
Virginia Van Keulen ◽  
Svetlana Bornschlegl ◽  
Allen Dietz ◽  
Mike Gustafson

1992 ◽  
Vol 10 (6) ◽  
pp. 1001-1006 ◽  
Author(s):  
V W Rusch ◽  
D Niedzwiecki ◽  
Y Tao ◽  
C Menendez-Botet ◽  
A Dnistrian ◽  
...  

PURPOSE Intrapleural cisplatin-based chemotherapy has been used in the treatment of patients with malignant pleural mesothelioma and malignant pleural effusions, but the pharmacokinetics of this form of chemotherapy have not been previously evaluated. We performed pharmacokinetic studies on 12 patients who received both intrapleural cisplatin and mitomycin immediately following pleurectomy/decortication for malignant pleural mesothelioma. PATIENTS AND METHODS Simultaneous pleural fluid and plasma samples were collected at 15 and 30 minutes, and at 1, 2, 3, 4, and 24 hours after administration of the intrapleural chemotherapy (cisplatin 100 mg/m2 and mitomycin 8 mg/m2), and after cisplatin (total and free) and mitomycin levels were measured. The mean peak levels, the areas under the concentration-time curve (AUC) and the drug half-lives (t1/2s) in plasma and pleural fluid were compared using the paired t test. Differences were considered significant if P less than or equal to .05. RESULTS Systemic absorption was rapid, with peak plasma levels being reached within 1 hour of administration of the intrapleural chemotherapy. Peak plasma levels measured after intrapleural chemotherapy approximated those reportedly attained during systemic administration of these drugs at similar doses. However, the mean peak cisplatin and mitomycin levels, and their mean AUCs, were significantly higher in the pleural fluid than in the plasma. There was a three- to fivefold advantage (on a logarithmic scale) for pleural to plasma AUCs for both cisplatin and mitomycin. The mean t1/2s for cisplatin and mitomycin were significantly longer in the plasma than in the pleural fluid. CONCLUSIONS The pharmacokinetics of intrapleural cisplatin-based chemotherapy are analogous to those of intraperitoneal chemotherapy. Our findings show that intrapleural cisplatin-based chemotherapy has a distinct local pharmacologic advantage, but also produces significant and sustained drug plasma levels.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7080-7080
Author(s):  
Kazue Yoneda ◽  
Fumihiro Tanaka ◽  
Shunichi Fukuda ◽  
Hayato Orui ◽  
Masaki Hashimoto ◽  
...  

7080 Background: Circulating tumor cell (CTC) is a surrogate of distant metastasis, and our preliminary study suggested that CTC detected by an EpCAM-based immuno-magnetic separation system (“CellSearch”) was a useful clinical marker in the diagnosis of malignant pleural mesothelioma (MPM) (Tanaka F. et al ASCO 2008). Methods: Patients who presented at our institute to receive pleural biopsy with suspicion of MPM were prospectively enrolled. CTCs in 7.5mL of peripheral blood were quantitatively evaluated with the CellSearch system. Results: Among 136 eligible patients, 104 were finally diagnosed with MPM, and 32 were with non-malignant diseases (NM). CTC was positive (CTC≥1) in 32.7% (37/104) of MPM pts, and in 9.4% (3/32) of NM pts (p=0.011). CTC-count was significantly higher in MPM (range, 0-9) than in NM (range, 0-1; p=0.007). According to a ROC curve analysis, the CTC-test provided a significant diagnostic performance in discrimination between MPM and NM (AUC= 0.623; P=0.036). Among MPM pts, CTC-positivity and CTC-count were significantly increased with tumor progression (p=0.026 and p=0.008, respectively). For all MPM pts, there was no significant difference in overall survival between CTC-positive and negative pts. However, in a planned subset analysis, CTC was a significant factor to predict poor prognosis (median survival time, 8.0 months for CTC-positive pts, and 20.3 months for negative pts; p=0.012) in pts with epithelioid-type MPM in which CTC was exclusively positive; a multivariate analysis confirmed that CTC, along with PS, was an independent prognostic factor (HR=2.38; P=0.006). Conclusions: CTC was a significant diagnostic marker in discrimination between MPM and NM. CTC-positivity was a significant and independent prognostic factor to predict a poor prognosis of epithelioid MPM. [Table: see text]


2014 ◽  
Vol 110 (8) ◽  
pp. 2040-2046 ◽  
Author(s):  
C Otterstrom ◽  
A Soltermann ◽  
I Opitz ◽  
E Felley-Bosco ◽  
W Weder ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document